Literature DB >> 28635520

Information for Clinicians: Approach to the patient with progressive radioactive iodine refractory thyroid cancer- When to use systemic therapy.

Maria Cabanillas1, David James Terris2, Mona Sabra3.   

Abstract

N/A.

Entities:  

Year:  2017        PMID： 28635520     DOI： 10.1089/thy.2016.0578

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


  5 in total

Review 1.  2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer.

Authors:  Laura Fugazzola; Rossella Elisei; Dagmar Fuhrer; Barbara Jarzab; Sophie Leboulleux; Kate Newbold; Jan Smit
Journal:  Eur Thyroid J       Date:  2019-08-28

Review 2.  Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.

Authors:  Carrie C Lubitz; Peter M Sadow; Gilbert H Daniels; Lori J Wirth
Journal:  Thyroid       Date:  2021-06-22       Impact factor: 6.506

3.  AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer.

Authors:  Francesca Collina; Lucia La Sala; Federica Liotti; Nella Prevete; Elvira La Mantia; Maria Grazia Chiofalo; Gabriella Aquino; Laura Arenare; Monica Cantile; Giuseppina Liguori; Francesca Di Gennaro; Luciano Pezzullo; Nunzia Simona Losito; Giancarlo Vecchio; Gerardo Botti; Rosa Marina Melillo; Renato Franco
Journal:  Cancers (Basel)       Date:  2019-06-07       Impact factor: 6.639

4.  CITED1 contributes to the progression of papillary thyroid carcinoma via the Wnt/β-catenin signaling pathway.

Authors:  Ying Wang; Huan Huang; Fengqiong Hu; Jia Li; Lie Zhang; Hua Pang
Journal:  Onco Targets Ther       Date:  2019-08-21       Impact factor: 4.147

5.  Ubiquitin conjugating enzyme E2 C (UBE2C) may play a dual role involved in the progression of thyroid carcinoma.

Authors:  Cheng Xiang; Hai-Chao Yan
Journal:  Cell Death Discov       Date:  2022-03-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.